-
Study aim
-
Determining the effect of hypothermia on the frequency and severity of peripheral neuropathy caused by chemotherapy drugs
-
Design
-
A controlled, parallel-group, unblinded, randomized, phase 2 clinical trial of 60 patients. A table of random numbers will be used for randomization.
-
Settings and conduct
-
This study will be conducted in the Chemotherapy Center of Vasei Hospital in Sabzevar. Due to the nature of the study, it was not possible to blind the patients, the treating physician and the person investigating the evaluated outcomes to the group that the patient will be included in.
-
Participants/Inclusion and exclusion criteria
-
The study population includes breast cancer patients. Entry criteria included
Consenting to use the cooling device and completing the consent form, using one of the chemotherapy regimens containing drugs associated with peripheral neuropathy, appropriate performance level, age greater than 18 years and less than 75 years, and exclusion criteria including a history of melanoma. He had a history of cryoglobulinemia, systemic lupus erythematosus, and poorly controlled diabetes. Also, patients will be excluded from the study if they do not tolerate hypothermia and withdraw their consent.
-
Intervention groups
-
In the intervention group, patients will use cold gloves and slippers during chemotherapy.
-
Main outcome variables
-
Using the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) chemotherapy induced peripheral neuropathy (CIPN) 20, the severity of neuropathy was measured at the beginning of the study (before the start of the intervention) and session 6 and 12 chemotherapy and 3 months after completion of treatment will be done.